Statins and Their Role in Pre-Percutaneous Coronary Intervention

Statins and Their Role in Pre-Percutaneous Coronary Intervention,10.1007/s11886-010-0110-0,Current Cardiology Reports,Rosetta Melfi,Annunziata Nusca,G

Statins and Their Role in Pre-Percutaneous Coronary Intervention   (Citations: 2)
BibTex | RIS | RefWorks Download
Lipid-lowering therapy with statins reduces the risk of cardiovascular events in patients with coronary artery disease. Recent in vitro and in vivo studies demonstrated a low-density lipoprotein-independent action of this class of drugs, which appears to modulate endothelial function, inflammation, and thrombosis. Randomized studies showed a beneficial effect of short-term statin pretreatment in reducing periprocedural cardiac marker release in patients undergoing percutaneous coronary intervention (PCI). In particular, the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) investigators—initially in stable angina patients, then in patients with acute coronary syndrome, and then in patients already on chronic statin therapy—demonstrated an improvement in 30-day major adverse cardiac event rates, which were driven by a reduced rate of periprocedural myocardial infarction. Moreover, statin therapy at the time of PCI significantly decreased the incidence of contrast-induced nephropathy. These observations support high-dose statin pretreatment in all patients who are candidates for PCI.
Journal: Current Cardiology Reports , vol. 12, no. 4, pp. 295-301, 2010
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: